IntelliProve Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$3.01M
- Investors
-
13
IntelliProve General Information
Description
Developer of a healthcare platform designed for determining vital health parameters. The company's platform offers artificial intelligence-driven health monitoring technology that measures physiological and mental health parameters without the need for a medical device or wearable and by using a smartphone camera that is based on a combination of novel signal processing and computer vision technology, enabling patients to assess health within seconds.
Contact Information
Website
www.intelliprove.comCorporate Office
- Miriam Makebaplein 2
- 9000 Ghent
- Belgium
Corporate Office
- Miriam Makebaplein 2
- 9000 Ghent
- Belgium
IntelliProve Timeline
IntelliProve Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Seed Round | 19-Nov-2026 | $3.01M | Completed | Generating Revenue | ||
| 3. Seed Round | 22-Jan-2025 | Completed | Generating Revenue | |||
| 2. Seed Round | 15-Nov-2022 | $996K | $1.1M | Completed | Generating Revenue | |
| 1. Angel (individual) | 09-Sep-2021 | $101K | $101K | Completed | Startup |
IntelliProve Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Class C | ||||||||
| Class C | ||||||||
| Class B | ||||||||
| Ordinary | 3,956 | $9.24 | $9.24 | 1x | $9.24 | 1.74% | ||
| Ordinary | 7,912 | $6.53 | $6.53 | 1x | $6.53 | 3.48% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
IntelliProve Comparisons
Industry
Financing
Details
IntelliProve Competitors (21)
One of IntelliProve’s 21 competitors is Huma, a Venture Capital-Backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Huma | Venture Capital-Backed | London, United Kingdom | ||||
| Datos Health | Venture Capital-Backed | Tel Aviv, Israel | ||||
| icometrix | Formerly VC-backed | Leuven, Belgium | ||||
| AMC Health | Private Equity-Backed | New York, NY | ||||
| Binah.ai | Venture Capital-Backed | Ramat Gan, Israel |
IntelliProve Signals
IntelliProve Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority | |||
| Angel (individual) | Minority |
IntelliProve FAQs
-
When was IntelliProve founded?
IntelliProve was founded in 2021.
-
Where is IntelliProve headquartered?
IntelliProve is headquartered in Ghent, Belgium.
-
What is the size of IntelliProve?
IntelliProve has 21 total employees.
-
What industry is IntelliProve in?
IntelliProve’s primary industry is Other Healthcare Technology Systems.
-
Is IntelliProve a private or public company?
IntelliProve is a Private company.
-
What is IntelliProve’s current revenue?
The current revenue for IntelliProve is .
-
How much funding has IntelliProve raised over time?
IntelliProve has raised $6.25M.
-
Who are IntelliProve’s investors?
, , , , and are 5 of 13 investors who have invested in IntelliProve.
-
Who are IntelliProve’s competitors?
Huma, Datos Health, icometrix, AMC Health, and Binah.ai are some of the 21 competitors of IntelliProve.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process